190
Mahata SK, Mahata M, Wen G, Wong WB, Mahapatra NR, Hamilton BA et al (2004) The cat-
echolamine release-inhibitory “catestatin” fragment of chromogranin a: naturally occurring
human variants with different potencies for multiple chromaffin cell nicotinic cholinergic
responses. Mol Pharmacol 66:1180–1191
Marczin N, El-Habashi N, Hoare GS, Bundy RE, Yacoub M (2003) Antioxidants in myocardial
ischemia-reperfusion injury: therapeutic potential and basic mechanisms. Arch Biochem
Biophys 420:222–236
Matsui T, Li L, del Monte F, Fukui Y, Franke TF, Hajjar RJ et al (1999) Adenoviral gene transfer of
activated phosphatidylinositol 3′-kinase and Akt inhibits apoptosis of hypoxic cardiomyocytes
in vitro. Circulation 100:2373–2379
McCormick J, Barry SP, Sivarajah A, Stefanutti G, Townsend PA, Lawrence KM et al (2006)
Free radical scavenging inhibits STAT phosphorylation following in vivo ischemia/reperfusion
injury. FASEB J 20:2115–2117
Means CK, Miyamoto S, Chun J, Brown JH (2008) S1P1 receptor localization confers selectivity
for Gi-mediated cAMP and contractile responses. J Biol Chem 283:11954–11963
Meng L, Ye XJ, Ding WH, Yang Y, Di BB, Liu L, Huo Y (2011) Plasma catecholamine release-
inhibitory peptide catestatin in patients with essential hypertension. J Cardiovasc Med
(Hagerstown) 12:643–647
Metz-Boutigue MH, Kieffer AE, Goumon Y, Aunis D (2003) Innate immunity: involvement of new
neuropeptides. Trends Microbiol 11:585–592
Miyamoto S, Murphy AN, Brown JH (2008) Akt mediates mitochondrial protection in cardiomyo-
cytes through phosphorylation of mitochondrial hexokinase-II. Cell Death Differ 15:521–529
Murry CE, Jennings RB, Reimer KA (1986). Preconditioning with ischemia: a delay of lethal cell
injury in ischemic myocardium. Circulation 74:1124–36
Murry CE, Jennings RB, Reimer KA (1991) New insights into potential mechanisms of ischemic
preconditioning. Circulation 84:442–445
Negoro S, Kunisada K, Tone E, Funamoto M, Oh H, Kishimoto T et al (2000) Activation of JAK/
STAT pathway transduces cytoprotective signal in rat acute myocardial infarction. Cardiovasc
Res 47:797–805
Negoro S, Oh H, Tone E, Kunisada K, Fujio Y, Walsh K et al (2001) Glycoprotein 130 regu-
lates cardiac myocyte survival in doxorubicin-induced apoptosis through phosphatidylinositol
3-kinase/Akt phosphorylation and Bcl-xL/caspase-3 interaction. Circulation 103:555–561
Newton AC (2003) Regulation of the ABC kinases by phosphorylation: protein kinase C as a para-
digm. Biochem J 370:361–371
O’Connor DT, Kailasam MT, Kennedy BP, Ziegler MG, Yanaihara N, Parmer RJ (2002) Early
decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of
hypertension. J Hypertens 20:1335–1345
O’Rourke B (2000) Myocardial K(ATP) channels in preconditioning. Circ Res 87:845–855
Oldenburg O, Cohen MV, Yellon DM, Downey JM (2002) Mitochondrial KAT P channels: role in
cardioprotection. Cardiovasc Res 55:429–437
Oldenburg O, Qin Q, Krieg T, Yang XM, Philipp S, Critz SD et al (2004) Bradykinin induces mito-
chondrial ROS generation via NO, cGMP, PKG, and mitoKATP channel opening and leads to
cardioprotection. Am J Physiol Heart Circ Physiol 286:H468–H476
Omland T, Dickstein K, Syversen U (2003) Association between plasma chromogranin A concen-
tration and long-term mortality after MI. Am J Med 114:25–30
Pagliaro P (2003) Differential biological effects of products of nitric oxide (NO) synthase: it is not
enough to say NO. Life Sci 73:2137–2149
Pagliaro P, Gattullo D, Rastaldo R, Losano G (2001) Ischemic preconditioning: from the first to the
second window of protection. Life Sci 69:1–15
Pagliaro P, Penna C (2015) Redox signalling and cardioprotection: translatability and mechanism.
Br J Pharmacol 172:1974–1995
C. Penna and P. Pagliaro